|
1
|
Yang H, Bai J, Li L, Yang Y, Zhang Y, Lv H, Fu S. Association of C-peptide level with bone mineral density in type 2 diabetes mellitus. Osteoporos Int 2023:10.1007/s00198-023-06785-9. [PMID: 37204453 DOI: 10.1007/s00198-023-06785-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 05/01/2023] [Indexed: 05/20/2023]
Abstract
This study revealed that there was no significant linear relationship between fasting C-peptide (FCP) level and bone mineral density (BMD) or fracture risk in type 2 diabetes mellitus (T2DM) patients. However, in the FCP ≤ 1.14 ng/ml group, FCP is positively correlated with whole body (WB), lumbar spine (LS), and femoral neck (FN) BMD and negatively correlated with fracture risk. PURPOSE To explore the relationship between C-peptide and BMD and fracture risk in T2DM patients. METHODS 530 T2DM patients were enrolled and divided into three groups by FCP tertiles, and the clinical data were collected. BMD was measured by dual-energy X-ray absorptiometry (DXA). The 10-year probability of major osteoporotic fractures (MOFs) and hip fractures (HFs) was evaluated by adjusted fracture risk assessment tool (FRAX). RESULTS In the FCP ≤ 1.14 ng/ml group, FCP level was positively correlated with WB, LS, and FN BMD, while FCP was negatively correlated with fracture risk and osteoporotic fracture history. However, FCP was not correlated with BMD and fracture risk and osteoporotic fracture history in the 1.14 < FCP ≤ 1.73 ng/ml and FCP > 1.73 ng/ml groups. The study has shown that FCP was an independent factor influencing BMD and fracture risk in the FCP ≤ 1.14 ng/ml group. CONCLUSIONS There is no significant linear relationship between FCP level and BMD or fracture risk in T2DM patients. In the FCP ≤ 1.14 ng/ml group, FCP is positively correlated with WB, LS, and FN BMD and negatively correlated with fracture risk, and FCP is an independent influencing factor of BMD and fracture risk. The findings suggest that FCP may predict the risk of osteoporosis or fracture in some T2DM patients, which has a certain clinical value.
Collapse
Affiliation(s)
- Hong Yang
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China
| | - Jia Bai
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China
| | - Lingling Li
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China
| | - Ying Yang
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China
| | - Yangyang Zhang
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China
| | - Haihong Lv
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
| | - Songbo Fu
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
| |
Collapse
|
|
2
|
Maurotti S, Russo C, Musolino V, Nucera S, Gliozzi M, Scicchitano M, Bosco F, Morittu VM, Ragusa M, Mazza E, Pujia R, Gazzaruso C, Britti D, Valenti MT, Deiana M, Romeo S, Giannini S, Dalle Carbonare L, Mollace V, Pujia A, Montalcini T. Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats. Calcif Tissue Int 2020; 107:266-280. [PMID: 32607636 DOI: 10.1007/s00223-020-00716-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 06/18/2020] [Indexed: 12/18/2022]
Abstract
C-peptide therapy protects against diabetic micro- and macrovascular damages and neuropatic complications. However, to date, the role of C-peptide in preventing diabetes-related bone loss has not been investigated. Our aim was to evaluate if C-peptide infusion improves bone quality in diabetic rats. Twenty-three male Wistar rats were randomly divided into three groups: normal control group; sham diabetic control group; diabetic plus C-peptide group. Diabetes was induced by streptozotocin injection and C-peptide was delivered subcutaneously for 6 weeks. We performed micro-CT and histological testing to assess several trabecular microarchitectural parameters. At the end, diabetic plus C-peptide rats had a higher serum C-peptide (p = 0.02) and calcium (p = 0.04) levels and tibia weight (p = 0.02) than the diabetic control group. The diabetic plus C-peptide group showed a higher trabecular thickness and cross-sectional thickness than the diabetic control group (p = 0.01 and p = 0.03). Both the normal control and diabetic plus C-peptide groups had more Runx-2 and PLIN1 positive cells in comparison with the diabetic control group (p = 0.045 and p = 0.034). Diabetic rats receiving C-peptide had higher quality of trabecular bone than diabetic rats not receiving this treatment. If confirmed, C-peptide could have a role in improving bone quality in diabetes.
Collapse
Affiliation(s)
- Samantha Maurotti
- Department of Medical and Surgical Science, Magna Græcia University of Catanzaro, 88100, Catanzaro, Italy
| | - Cristina Russo
- Department of Clinical and Experimental Medicine, Magna Græcia University of Catanzaro, Viale S. Venuta, 88100, Catanzaro, Italy
| | - Vincenzo Musolino
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Saverio Nucera
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Micaela Gliozzi
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Miriam Scicchitano
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Francesca Bosco
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Valeria Maria Morittu
- Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Monica Ragusa
- Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Elisa Mazza
- Department of Medical and Surgical Science, Magna Græcia University of Catanzaro, 88100, Catanzaro, Italy
| | - Roberta Pujia
- Department of Medical and Surgical Science, Magna Græcia University of Catanzaro, 88100, Catanzaro, Italy
| | - Carmine Gazzaruso
- Diabetes and Endocrine and Metabolic Diseases Unit and the Centre for Applied Clinical Research (Ce.R.C.A.) Clinical Institute "Beato Matteo" (Hospital Group San Donato), 27029, Vigevano, Italy
| | - Domenico Britti
- Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Maria Teresa Valenti
- Department of Medicine, Specialized Regional Center for Biomolecular and Histomorphometric Research On Degenerative and Skelatal Diseases, Verona, Italy
| | - Michela Deiana
- Department of Medicine, Specialized Regional Center for Biomolecular and Histomorphometric Research On Degenerative and Skelatal Diseases, Verona, Italy
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134, Verona, Italy
| | - Stefano Romeo
- Department of Medical and Surgical Science, Magna Græcia University of Catanzaro, 88100, Catanzaro, Italy
- Department of Molecular and Clinical Medicine, Sahlgrenska Center for Cardiovascolar and Metabolic Research, University of Gothenburg, 42246, Göteborg, Sweden
| | - Sandro Giannini
- Department of Medicine, University of Padova and Regional Center for Osteoporosis, Clinica Medica 1, Padova, Italy
| | - Luca Dalle Carbonare
- Department of Medicine, Specialized Regional Center for Biomolecular and Histomorphometric Research On Degenerative and Skelatal Diseases, Verona, Italy
| | - Vincenzo Mollace
- IRC-FSH Interregional Center for Food Safety and Health, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy
| | - Arturo Pujia
- Department of Medical and Surgical Science, Magna Græcia University of Catanzaro, 88100, Catanzaro, Italy
| | - Tiziana Montalcini
- Department of Clinical and Experimental Medicine, Magna Græcia University of Catanzaro, Viale S. Venuta, 88100, Catanzaro, Italy.
| |
Collapse
|
|
3
|
Lv R, Chen Y, Xia N, Liang Y, He Q, Li M, Qi Z, Lu Y, Zhao S. Development of a double-antibody sandwich ELISA for rapid detection to C-peptide in human urine. J Pharm Biomed Anal 2018; 162:179-184. [PMID: 30261444 DOI: 10.1016/j.jpba.2018.07.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 07/18/2018] [Accepted: 07/29/2018] [Indexed: 01/18/2023]
Abstract
C-peptide level is recognized as an important indicator of diabetes diagnosis. A sensitive and specific double-antibody sandwich enzyme-linked immunosorbent assay for the detection of C-peptide based on double antibody sandwich method was studied in this paper. The rabbit and hen were innunized with PLL-C-peptide and BSA-C-peptide respectively to obtain specific Yolk antibody (IgY) and polyclonal antibody used to construct the sandwich ELISA for the measurement of C-peptide. The limit of detection was 0.51 μg/mL and the half maximal inhibitory concentration (IC50) was 3.26 μg/mL. The method developed in the study showed no evident cross-reactivity with other similar analogs. The detection standard curve of C-peptide exhibited a good linearity (R2 = 0.9896, n = 15). 17 types of the urine of diabetes patients on c-peptide levels compared with the hospital type of diabetes information, with a conclusion of a high consistent rate. Therefore, the methods could be selectively used for rapid screening of C-peptide in human urine, and the type of diabetes has some referential significance.
Collapse
Affiliation(s)
- Rui Lv
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Yingshan Chen
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Nana Xia
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Yuxin Liang
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Qiyi He
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Minyou Li
- Guangzhou Jinde Biotechnology Co., LTD, Guangzhou 510663, People's Republic of China.
| | - Zongxian Qi
- Guangzhou Jinde Biotechnology Co., LTD, Guangzhou 510663, People's Republic of China.
| | - Yeyu Lu
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| | - Suqing Zhao
- Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China.
| |
Collapse
|